Objective: To compare the efficacy of oral rizatriptan 10 mg with oral doses of sumatriptan, naratriptan, and zolmitriptan on stringent outcome measures.
Methods: Retrospective analysis of data from five randomized, placebo-controlled, double-masked clinical trials in which oral rizatriptan was directly compared with oral sumatriptan 100 mg (n = 772), 50 mg (n = 1116), 25 mg (n = 1183), naratriptan 2.5 mg (n = 413), and zolmitriptan 2.5 mg (n = 580) for the acute treatment of a moderate or severe migraine attack.
Outcome Measures: Percentage of patients pain-free at 2 hours, symptom-free at 2 hours (no pain, nausea, photophobia, phonophobia, vomiting, or functional disability), 24-hour sustained pain-free (no headache at 2 hours, no recurrence, and no additional antimigraine medications for 24 hours).
Results: More patients taking rizatriptan 10 mg were pain-free at 2 hours than were patients taking sumatriptan 100 mg (40% vs 33%, p = 0.019), sumatriptan 50 mg (40% vs 35%, p = 0.009), sumatriptan 25 mg (38% vs 27%, p < 0.001), naratriptan 2.5 mg (45% vs 21%, p < 0.001), and zolmitriptan 2.5 mg (43% vs 36%, p = 0.041). More patients taking rizatriptan 10 mg were symptom-free at 2 hours than were patients taking sumatriptan 100 mg (31% vs 22%, p = 0.002), sumatriptan 50 mg (33% vs 28%, p = 0.003), sumatriptan 25 mg (33% vs 24%, p < 0.001), naratriptan 2.5 mg (30% vs 11%, p < 0.001), and zolmitriptan 2.5 mg (31% vs 24%, p = 0.042). More patients taking rizatriptan 10 mg had a 24-hour sustained pain-free response than did patients taking sumatriptan 100 mg (27% vs 23%, p = 0.112), sumatriptan 50 mg (30% vs 26%, p = 0.015), sumatriptan 25 mg (27% vs 20%, p = 0.005), naratriptan 2.5 mg (29% vs 17%, p = 0.004), and zolmitriptan 2.5 mg (32% vs 24%, p = 0.013).
Conclusion: Oral rizatriptan 10 mg was more effective than oral sumatriptan, naratriptan, and zolmitriptan on stringent outcome measures of pain-free response at 2 hours, symptom-free response at 2 hours, and 24-hour sustained pain-free response.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1212/wnl.57.8.1377 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
World neurology updates: Other primary headache disorder - Treatment.
eNeurologicalSci
December 2024
NIHR King's Clinical Research Facility and Wolfson Sensory, Pain and Regeneration Centre, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, UK.
•The trigeminal autonomic cephalalgias are a severe disabling form of primary headache disorders characterized by severe unilateral pain commonly associated with ipsilateral cranial autonomic features as well as a sense of restlessness or agitation, of which the most common is cluster headache.•Different forms of trigeminal autonomic cephalalgias include cluster headache, paroxysmal hemicrania (PH), hemicrania continua (HC), short lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT)/short lasting unilateral neuralgiform headache attacks with cranial autonomic symptoms (SUNA) and are differentiated based on their duration and frequency•Triptans, such as sumatriptan by injection, high flow 100 % oxygen by face mask, or non-invasive vagus nerve stimulation, are mainstay acute treatments of attacks of cluster headache.•Interim preventive treatments to reduce attack frequency include a short course of high dose oral corticosteroids, local anesthetic/corticosteroid injection around the homolateral (to pain) greater occipital nerve or the CGRP monoclonal antibody galcanezumab.
View Article and Find Full Text PDFAssessment of pharmacokinetic and pharmacodynamic interactions between zavegepant and sumatriptan: A phase 1, randomized, placebo-controlled study in healthy adults.
Headache
October 2024
Pfizer Inc., Groton, Connecticut, USA.
Article Synopsis
- The study aimed to assess how zavegepant and sumatriptan interact pharmacodynamically (PD) and pharmacokinetically (PK) when administered together in healthy adults to understand their effects on migraine treatment.
- Zavegepant, a nasal spray for migraine, and sumatriptan, an injectable triptan, have different mechanisms and possible side effects, particularly concerning blood pressure, making their interaction important for possible joint use in patients.
- The Phase 1 study involved 42 participants and found that blood pressure and safety were generally unchanged when both drugs were taken together, suggesting they may be safe to coadminister.
Development and Evaluation of Chemometric Models for the Estimation of Sumatriptan in the Presence of Naproxen and a Degradation Product Using UV Spectrophotometry.
J AOAC Int
October 2024
Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ahram Canadian University, 12566, 6th October, Cairo, Egypt.
Article Synopsis
- Chemometrics provides a way to analyze the spectral characteristics of drugs, making it a useful alternative to traditional chromatography for studying pharmaceutical formulations, particularly when assessing drug stability.
- The study focuses on Sumatriptan (SUM), used in migraine treatment, showing that no stability-indicating chemometric approaches have been applied to it, highlighting the need for accurate measurement methods in the presence of its co-formulant, naproxen (NAP).
- Three multivariate calibration methods—classical least-squares (CLS), partial least-squares regression (PLS), and principal components regression (PCR)—were utilized to analyze SUM, with PLS yielding the most accurate results, demonstrating high precision in the quantitative analysis when compared to traditional methods
Rutaecarpine alleviates migraine in nitroglycerin-induced mice by regulating PTEN/PGK1 signaling pathway to activate NRF2 antioxidant system.
Biomed Pharmacother
October 2023
Department of Neurosurgery, Changshu No.2 People's Hospital, The Affiliated Changshu Hospital of Nantong University, 215500 Jiangsu Province, China. Electronic address:
Background: Due to its widespread prevalence, migraine is a common neurovascular condition that has a major impact on people's health and quality of life. Rutaecarpine (RUT) is one of the main effective components of Evodia rutaecarpa, which has a wide range of biological activities. However, the exact mechanism by which RUT improves migraine remain unknown.
View Article and Find Full Text PDFEuropean Academy of Neurology guidelines on the treatment of cluster headache.
Eur J Neurol
October 2023
Danish Headache Center, Department of Neurology, Rigshospitalet-Glostrup, University of Copenhagen, Copenhagen, Denmark.
Background And Purpose: Cluster headache is a relatively rare, disabling primary headache disorder with a major impact on patients' quality of life. This work presents evidence-based recommendations for the treatment of cluster headache derived from a systematic review of the literature and consensus among a panel of experts.
Methods: The databases PubMed (Medline), Science Citation Index, and Cochrane Library were screened for studies on the efficacy of interventions (last access July 2022).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!